2010
DOI: 10.1016/j.peptides.2010.03.037
|View full text |Cite
|
Sign up to set email alerts
|

A fowlicidin-1 analog protects mice from lethal infections induced by methicillin-resistant Staphylococcus aureus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
18
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 33 publications
(18 citation statements)
references
References 25 publications
0
18
0
Order By: Relevance
“…To compare the relative HDP-inducing efficacy of saturated free fatty acids in pigs, IPEC-J2 cells were treated first with a broad range of doses of different fatty acids with the chain length varying from C1 to C18 for 24 h, and the cytotoxicity was examined as we previously described [35][37]. Generally, fatty acids showed an enhanced toxicity as the aliphatic chain length increased (data not shown).…”
Section: Resultsmentioning
confidence: 97%
“…To compare the relative HDP-inducing efficacy of saturated free fatty acids in pigs, IPEC-J2 cells were treated first with a broad range of doses of different fatty acids with the chain length varying from C1 to C18 for 24 h, and the cytotoxicity was examined as we previously described [35][37]. Generally, fatty acids showed an enhanced toxicity as the aliphatic chain length increased (data not shown).…”
Section: Resultsmentioning
confidence: 97%
“…Since cathelicidins have membrane-perturbing properties which might affect the host’s cell membrane153132333435, first the possible cytotoxicity of the cathelicidins to RAW264.7 cells was assessed. No or very limited cytotoxicity was observed for most cathelicidins.…”
Section: Resultsmentioning
confidence: 99%
“…In addition, cathelicidins have been shown to have therapeutic potential. Overexpression of cathelicidin in a lung xenograft model has been shown to promote P. aeruginosa and S. aureus killing12, while exogenous cathelicidin treatment has been successfully used to inhibit M. haemolytica, E. coli and S. aureus infections131415.…”
mentioning
confidence: 99%
“…According to the APD [9], more than a dozen of peptides have been expressed in plants to reduce or avoid infection. In addition, lactoferricin, distinctin, ranalexin, halocidin, polybia-MPI, chicken cathelicidin 1 (fowlicidin-1), bacterial mutacin B-Ny266, and bacterial ABP-118 have been tested in mice models [73][74][75][76][77][78][79][80]. Other engineered peptides or AMP mimics that have been evaluated in animal models include D, L-peptides, WLBU2, Pro-rich A3-APO, and acyl-lysyl oligomers [81][82][83][84].…”
Section: Therapeutic Potentials Of Ampsmentioning
confidence: 99%
“…Some of the post-translational strategies, such as C-terminal amidation, cyclization, D-amino acid incorporation, and halogenation, have been adopted in laboratories to enhance peptide stability to proteases. As a consequence, several engineered peptides have been demonstrated to be able to keep animal healthy [73][74][75][76][77][78][79][80][81][82][83][84].…”
Section: Concluding Remarks and Future Directionsmentioning
confidence: 99%